MALDI–MSI Pilot Study Highlights Glomerular Deposits of Macrophage Migration Inhibitory Factor as a Possible Indicator of Response to Therapy in Membranous Nephropathy
PROTEOMICS - CLINICAL APPLICATIONS2018Vol. 13(3), pp. e1800019–e1800019
Citations Over Time
Vincenzo L’Imperio, Andrew Smith, Elena Ajello, Isabella Piga, Martina Stella, Vanna Denti, Silvia Tettamanti, Renato Alberto Sinico, Federico Pieruzzi, Maurizio Garozzo, Gisella Vischini, Manuela Nebuloni, Fabio Pagni, Fulvio Magni
Abstract
Despite much effort being made in recent years to understand the pathogenesis of MN, a biomarker able to predict the outcome of these patients following therapeutic treatment is still lacking. Here, a protein (MIF), verified by immunohistochemistry, that can differentiate between these MN patients and could be a valuable starting point for a further study focused on verifying its predictive role in therapy response is highlighted.
Related Papers
- → The Role of PLA2R Antibody in Treatment of Membranous Nephropathy(2017)20 cited
- → Thrombosis praecox: Thromboembolic complication preceding the onset of overt Nephrotic syndrome in a patient with Membranous Nephropathy(2022)1 cited
- → Nephrotic syndrome due to membranous nephropathy as the cause of rising TSH levels or primary hypothyroidism as the cause of nephrotic syndrome? A case report(2015)
- Incidence of nephrotic syndrome in patients with glomerulonephritis.(1986)
- → [Adult Segmental Membranous Nephropathy Presenting As Nephrotic Syndrome: A Rare Case Report and Literature Review].(2023)